[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-331838-105":59,"doc-detail-331838-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-promising-target-for-breast-cancer-b7-h3","A promising target for breast cancer: B7-H3","","Breast cancer is a leading global cause of women’s cancer mortality, driven by diverse genetic and environmental factors. Conventional therapies have limited ability to extend survival, motivating intensive research over the past decade. B7-family immunomodulatory checkpoint proteins have transformed cancer treatment, with B7-H3 gaining attention for demodulation and immune regulatory effects. Dysregulated B7-H3 expression correlates with poor prognosis and supports immune evasion, promoting proliferation, metastasis, and drug resistance. This review details B7-H3 structure and regulation, its dual costimulatory/coinhibitory roles in cancer and normal physiology, and targeted drugs aimed at improving breast cancer therapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-promising-target-for-breast-cancer-b7-h3/331838/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-promising-target-for-breast-cancer-b7-h3/331838.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is B7-H3 considered a promising target for breast cancer therapy?","Question",{"text":113,"@type":114},"B7-H3 has significant immune modulatory effects and its uncontrolled expression is strongly linked to poor outcomes. It promotes immune evasion and supports tumor survival, proliferation, metastasis, and drug resistance in breast cancer cells.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What roles does B7-H3 play according to the review?",{"text":118,"@type":114},"The review explains B7-H3’s structure and regulation and describes its double costimulatory/coinhibitory functions within cancer and normal physiology. It also details how B7-H3 contributes to malignant behavior and tumor microenvironment dynamics.",{"name":120,"@type":111,"acceptedAnswer":121},"How are breast cancer molecular subtypes used in therapy decisions?",{"text":122,"@type":114},"Breast malignancies are categorized into molecular subtypes based on gene expression profiling and receptor status. Biomarkers such as ER, PR, HER2, and Ki67 help indicate treatment relevance, including endocrine therapy for ER-α positive cancers and HER2-directed agents for HER2-positive malignancies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},331838,1790672168,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Jiang et al. BMC Cancer (2024) 24:182 [https://doi.org/10.1186/s12885-024-11933-3](https://doi.org/10.1186/s12885-024-11933-3)  \nBMC Cancer  \n REVIEW Open Access  \nA promising target for breast cancer: B7-H3  \nYing Jiang1, Jiayu Liu1, Lingyan Chen2, Zhiwen Qian2 andYan Zhang1,2*  \nAbstract  \nBreast cancer (BC) is the second-leading factor of mortality for women globally and is brought on by a variety of genetic and environmental causes. The conventional treatments for this disease have limitations, making it difficult to improve the lifespan of breast cancer patients. As a result, extensive research has been conducted  \nover the past decade to find innovative solutions to these challenges. Targeting of the antitumor immune response through the immunomodulatory checkpoint protein B7 family has revolutionized cancer treatment and led to intermittent patient responses. B7-H3 has recently received attention because of its significant demodulation and its immunomodulatory effects in many cancers. Uncontrolled B7-H3 expression and a bad outlook are strongly associated, according to a substantial body of cancer research. Numerous studies have shown that BC has significant B7-H3 expression, and B7-H3 induces an immune evasion phenotype, consequently enhancing the survival, proliferation, metastasis, and drug resistance of BC cells. Thus, an innovative target for immunotherapy against BC may bethe B7-H3 checkpoint.  \nIn this review, we discuss the structure and regulation of B7-H3 and its double costimulatory/coinhibitory function within the framework of cancer and normal physiology. Then we expound the malignant behavior of B7-H3 in BC and its role in the tumor microenvironment (TME) and finally focus on targeted drugs against B7-H3 that have opened new therapeutic opportunities in BC.  \nKeywords Breast cancer, B7-H3, Immune checkpoint, Cancer immunotherapy, Tumor microenvironment, Targeted immunotherapy  \nIntroduction  \nBC is the leading cause of disability and death among women globally [1]. The World Health Organization reports that approximately 2.26 million women are given a BC diagnosis every year [1]. Mosaic populations of tumor cells, immune cells, and stromal cells that have different genetic, epigenetic, and phenotypic traits make up breast malignancies. Four molecular subtypes of BC were categorized by gene expression sequence analysis; these  \n*Correspondence: Yan Zhang [fuyou2007@126.com](fuyou2007@126.com)  \n1 Department of Oncology, Wuxi Maternal and Child Health Care Hospital, Women’s Hospital of Jiangnan University, Jiangnan University, Wuxi 214002, China  \n2 Wuxi Maternal and Child Health Hospital, Nanjing Medical University, Wuxi 214000, China  \ninclude Luminal A, if estrogen receptor alpha-positive (ER) + and/or progesterone-receptor (PR) + , human epidermal growth factor receptor 2 (HER2) − , Ki67 \u003C 14%), Luminal B (if ER +and/or PR + , HER2 overexpressed or Ki67 ≥14%), triple-negative breast cancer (TNBC)(if ER − , PR − , HER2 −), and HER2-enriched (if ER − , PR −and HER2 +) [2]. The specific receptors that cancer cells express (or do not express) act as biomarkers for therapy. Anti-estrogens and aromatase inhibitors, both of which disrupt ER activity, are effective against ER-α positive cancers [3]. Therapeutic agents directed at HER2, such as trastuzumab—an anti-HER2 antibody—demonstrate anticancer efficacy specifically in HER2-positive malignancies [4]. Hormone-responsive BC has been successfully treated with endocrine treatment. Regretfully, disease recurrence and relapse are caused by the emergence of drug resistance [5], TNBC has the poorest  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes","cbCair2h3CTCiHb8","https://ap.wps.com/l/cbCair2h3CTCiHb8","pdf",1505033,17,"English","# Introduction\n## Breast cancer burden and molecular subtypes\n## Immune checkpoint therapy and B7 family\n# B7-H3 biology in breast cancer\n## Structure and regulation\n## Dual costimulatory/coinhibitory functions\n# Tumor microenvironment roles\n# Targeted drugs against B7-H3","[{\"question\":\"Why is B7-H3 considered a promising target for breast cancer therapy?\",\"answer\":\"B7-H3 has significant immune modulatory effects and its uncontrolled expression is strongly linked to poor outcomes. It promotes immune evasion and supports tumor survival, proliferation, metastasis, and drug resistance in breast cancer cells.\"},{\"question\":\"What roles does B7-H3 play according to the review?\",\"answer\":\"The review explains B7-H3’s structure and regulation and describes its double costimulatory/coinhibitory functions within cancer and normal physiology. It also details how B7-H3 contributes to malignant behavior and tumor microenvironment dynamics.\"},{\"question\":\"How are breast cancer molecular subtypes used in therapy decisions?\",\"answer\":\"Breast malignancies are categorized into molecular subtypes based on gene expression profiling and receptor status. Biomarkers such as ER, PR, HER2, and Ki67 help indicate treatment relevance, including endocrine therapy for ER-α positive cancers and HER2-directed agents for HER2-positive malignancies.\"}]","A promising target for breast cancer: B7-H3 | PDF",1789995418,43]